Michael S. Hofman

Michael S. Hofman

Peter Maccallum Cancer Centre - Melbourne / Australia
Medical and Health Sciences / Nuclear Medicine
AD Scientific Index ID: 4389479
-
person_outline Michael S. Hofman's MOST POPULAR ARTICLES
1-) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised …MS Hofman, N Lawrentschuk, RJ Francis, C Tang, I Vela, P Thomas, ...The Lancet 395 (10231), 1208-1216, 202014542020
2-) Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and …M Perera, N Papa, D Christidis, D Wetherell, MS Hofman, DG Murphy, ...European urology 70 (6), 926-937, 201610982016
3-) [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyMS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ...The Lancet Oncology 19 (6), 825-833, 20189802018
4-) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution …M Perera, N Papa, M Roberts, M Williams, C Udovicich, I Vela, ...European urology 77 (4), 403-417, 20208552020
5-) [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...The Lancet 397 (10276), 797-804, 2021759*2021